Impact of erythropoietin treatment on the quality of life of oncologic patients

Clinical and Translational Oncology

Volumn 9, Issue 10, 2007, Pages 645-651

  Pelegri A ^a  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

Author keywords

Anaemia; Cancer; Erythropoietin; Quality of life

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN ALPHA; ERYTHROPOIETIN BETA; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; ANTINEOPLASTIC AGENT; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; FATIGUE; FUNCTIONAL STATUS; GENERAL CONDITION IMPROVEMENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; OXYGEN SATURATION; OXYGEN TISSUE LEVEL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; REVIEW; FEMALE; MALE; NEOPLASM;

ANEMIA; ANTINEOPLASTIC AGENTS; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; MALE; NEOPLASMS; QUALITY OF LIFE;

EID: 38449112458     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-007-0117-1     Document Type: Review

References (49)

1. Groopman JE, Itri LM (1999) Chemotherapy-induced anaemia in adults: incidence and treatment. J Natl Cancer Inst 91:1616-1634
2. Knight K, Wade S, Balducci L (2004) Prevalence and outcomes of anaemia in cancer: A systematic review of the literature. Am J Med 116[Suppl 7A]:11S-26S
3. Ludwig H, Van Belle S, Barrett-Lee P et al (2004) The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40:2293-2306
4. Cella D (1998) Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 25:43-46650
5. Crawford J, Cella D, Cleeland C et al (2002) Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemia cancer patients receiving epoetin alfa therapy. Cancer 95:888-895
6. Cella D, Kallich J, McDermott A et al (2004) The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: Results from five randomized clinical trials. Ann Oncol 15:979-986
7. Bokemeyer C, Aapro MS, Courdi A et al (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43:258-270
8. Cella D, Dobrez D, Glaspy J (2003) Control of cancer-related anemia with erythropoietic agents: A review of evidence for improved quality of life and clinical outcomes. Ann Oncol 14:511-519
9. Jones M, Schenkel B, Just J, Fallowfield L (2004) Epoetin alfa improves quality of life in patients with cancer: Results of a metaanalysis. Cancer 101:1720-1732
10. Gascon P (2005) Evaluating erythropoietic agents for the treatment of anaemia in the oncology setting. Eur J Cancer 41:2601-2612
11. Demetri GD, Kris M, Wade J et al (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response of tumor type: Results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16:3412-3425
12. Ludwig H, Strasser K (2001) Symptomatology of anemia. Semin Oncol 28[Suppl 8]:7-14
13. Stone P, Richards M, A'Hern R et al (2000) A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol 11:561-567
14. Curt G, Breitbart W, Cella D et al (2000) Impact of cancer-related fatigue on the lives of patients: New findings from the Fatigue Coalition. Oncologist 5:353-360
15. Carulla J, Escobar Y, Montalar J et al (2005) Estudio epidemiológico sobre la prevalencia de la astenia en pacientes oncológicos. Clin Transl Oncol 7[Suppl 1]:1-158
16. Yellen SB, Cella DF, Webster KA et al (1997) Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy Measurement System. J Pain Symptom Manage 13:63-74
17. Cella D (1997) The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34:13-19
18. Holzner B, Kemmler G, Greil R et al (2002) The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Ann Oncol 13:965-973
19. Cella D, Dobrez D, Glaspy J (2003) Control of cancer-related anemia with erythropoietic agents: A review of evidence for improved quality of life and clinical outcomes. Ann Oncol 14:511-519
20. Cella D, Eton D, Lai J et al (2002) Combining anchor and distribution based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) Anemia and Fatigue Scales. J Pain Symptom Manage 24:547-561
21. Kallich J, Tchekmedyian NS, Damiano A et al (2002) Psychological outcomes associated with anemia-related fatigue in cancer patients. Oncology 16[Suppl 9]:117-124
22. O'shaughenessy JA (2003) Chemotherapy-induced cognitive dysfunction: A clearer picture. Clin Breast Cancer 4[Suppl 2]:S89-S94
23. Mancuso A, Migliorino M, De Santis S et al (2006) Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy. Ann Oncol 17:146-150
24. Rizzo JD, Lichtin AE, Woolf SH et al (2002) Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20:4083-4107
25. Littlewood TJ, Bajetta E, Nortier JW et al (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865-2874
26. Bottomley A, Thomas R, Van Steen K et al (2003) Guidelines for the use of epoetin: Have quality-of-life benefits been proven? J Clin Oncol 21:2223-2224
27. Gabrilove JL, Cleeland CS, Livingston RB et al (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19:2875-2882
28. Witzig TE, Silberstein PT, Loprinzi CL et al (2005) Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 23:2606-2617
29. Chang J, Coutre F, Young S et al (2005) Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 12:2597-2605
30. Savonije JH, Groeningen CJ, Wormhoudt LW et al (2006) Early intervention with epoetin alfa during platinum-based chemotherapy: An analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level. Oncologist 11:206-216
31. Savonije JH, van Groeningen CJ, van Bochove A et al (2005) Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: results of a multicenter randomised controlled trial. Eur J Cancer 41: 1560-1569
32. Wilkinson PM, Antonopoulos M, Lahousen M et al (2006) Epoetin alfa in platinum-treated ovarian cancer patients: Results of a multinational, multicentre, randomised trial. Br J Cancer 94:947-954
33. Straus DJ, Testa M, Riggs SA et al (2003) Early treatment with epoetin alfa improves anemia, quality of life (QOL), and productivity in patients (pts) with hematologic malignancies and mild anemia during chemotherapy (CT). Blood 102:497a
34. Steensma D, Molina R, Sloan J et al (2006) Phase III study of different dosing schedules of erythropoietin in anemic patients with cancer. J Clin Oncol 24:1079-1089
35. Osterborg A, Brandberg Y, Molostova V et al (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol 20:2486-2494
36. Boogaerts M, Coiffier B, Kainz C et al (2003) Impact of epoetin beta on quality of life with malignant disease. Br J Cancer 88:988-995
37. Hedenus M, Hansen S, Taylor K et al (2002) Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 119:79-86
38. Vansteenkiste J, Pirker R, Massuti B et al (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94:1211-1220
39. Canon JL, Vansteenkiste J, Bodoky G et al (2006) Results of a randomised, double-blind, active-controlled trial of darbepoetin alfa administered once every 3 weeks for the treatment of anaemia in patients receiving multicycle chemotherapy. J Natl Cancer Inst 98:273-284
40. Waltzman R, Croot C, Justice JR et al (2005) Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 mcrog every 2 weeks) in anemic cancer patients receiving chemotherapy. Oncologist 10:642-650
41. Glaspy J, Vadhan-Raj S, Patel R et al (2006) Randomized comparison of every-2-weeks darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: The 20030125 Study Group trial. J Clin Oncol 24:2290-2297
42. Antonadou D, Cardamakis E, Puglisi M et al (2001) Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies. Final results of a randomized phase III study. Eur J Cancer 37[Suppl 6]:S144
43. Henke M, Laszig R, Rube C et al (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362:1255-1260
44. Goldberg P (2007) Danish researchers post long-awaited Aranesp results-ever so discretely. Interim analysis of Danish Head and Neck Cancer Group 10 trial. Cancer Lett 33:1-6
45. Wright J, Ung Y, Julian J et al (2007) Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25:1027-1032
46. Erythropoiesis Stimulating Agents: www.fdagov/medwatch/report.htm
47. Safety Alert Aranesp (darbepoetin alfa). www.fda.gov/medwatch/safety/ 2007/Aranesp_DHCP_012707.htm
48. Cancer and related anaemia. V.2007. www.nccn.org
49. Khuri F (2007). Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med 356; 2445-2448